• Quarterly cash flow report for Nexalis Therapeutics Limited
• $474,000 net cash used in operating activities
• $565,000 net cash from financing activities
• $511,000 cash and cash equivalents at quarter end

Nexalis Therapeutics Limited has released its Appendix 4C quarterly cash flow report for the period ended 31 March 2026. The report shows the company used $474,000 in operating activities, primarily for research and development, advertising and marketing, staff costs, and administration expenses. The company received $565,000 from financing activities, including $323,000 from the issue of equity securities and $281,000 from borrowings. This resulted in $511,000 in cash and cash equivalents at the end of the quarter, up from $436,000 in the previous quarter. The company has also disclosed details of its financing facilities, including a $38.5 million funding facility from Linlithgow Family Office to cover clinical trial costs, and a further $12.6 million facility to fund Phase 1 and 2 costs of its new oral Esketamine + CYP450 inhibitor fixed dose combination therapy, SRX-25.

The company has not provided any high-importance, price-sensitive forward-looking financial metrics or guidance.

The company has not provided any forward-looking outlook statements.